Core Viewpoint - Heptagon Pharmaceuticals-B (02142.HK) announced a share buyback of 200,000 shares at a cost of HKD 2.7 million on November 13 [1] Group 1 - The company executed a buyback program, indicating a commitment to returning value to shareholders [1] - The total expenditure for the buyback was HKD 2.7 million, reflecting the company's financial strategy [1] - The number of shares repurchased was 200,000, which may influence the stock's market performance [1]

公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年11月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | ...

Group 1 - The stock of Heptagon Pharmaceuticals-B (02142.HK) has increased by over 5%, currently up 5.46% at HKD 13.94 [1] - The trading volume reached HKD 17.1969 million [1]

Core Viewpoint - The stock of Heptagon Pharmaceuticals (02142) rose over 5%, currently up 5.46% at HKD 13.94, with a trading volume of HKD 17.1969 million, following the announcement of a strategic partnership with Evinova at the 8th China International Import Expo [1] Group 1: Strategic Partnership - Heptagon Pharmaceuticals and Evinova announced a strategic cooperation to leverage AI and digital technologies to enhance the efficiency of innovative biotherapy development [1] - The partnership aims to build an AI-driven open ecosystem for drug research and development by utilizing each company's strengths [1] Group 2: AI Platform Development - Heptagon Pharmaceuticals launched its first fully human AIHCAb model driven by the Hu-mAtrIx™ AI platform during a global R&D day event in Shanghai [1] - The model is based on proprietary HarbourMice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] - Unlike traditional screening methods, the platform achieves a closed-loop process of AI design, intelligent screening, and wet lab validation [1]

Core Viewpoint - The stock of Heptagon Pharmaceuticals (02142) rose over 5%, currently up 5.46% at HKD 13.94, with a trading volume of HKD 17.1969 million, following the announcement of a strategic partnership with Evinova at the 8th China International Import Expo to enhance the efficiency of innovative biotherapy development through AI and digital technologies [1] Group 1 - Heptagon Pharmaceuticals and Evinova will leverage their respective strengths to build an AI-driven open ecosystem for drug development [1] - The company recently launched its first fully human AIHCAb model driven by the Hu-mAtrIx AI platform during a global R&D day event in Shanghai [1] - The AIHCAb model is based on proprietary HarbourMice platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] Group 2 - The platform differs from traditional screening methods by achieving a closed-loop process of AI design, intelligent screening, and wet lab validation [1]

Group 1 - The company, HAPO Pharmaceutical-B (02142), announced a share buyback plan [1] - The company will spend HKD 1.978 million to repurchase 150,000 shares [1]

Group 1 - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan, intending to repurchase 150,000 shares at a cost of HKD 1.978 million [1]

格隆汇11月11日丨和铂医药-B(02142.HK)公告，11月11日耗资198万港元回购15万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年11月11日 | 3). | 就根據股份計劃授予參與人（發行人的董事除外）的股份獎勵或期權 | 30,000 | 0.0034 % | HKD | 0 | | | --- | --- | --- | --- | --- | --- | --- | | | 而發行新股或轉讓庫存股份 - 涉及新股 | | | | | | | | 根據於2020年11月23日採納及獲本公司股東批准的首次公開發售後 | | | | | | | | 股份獎勵計劃而發行普通股以滿足股份獎勵 | | | | | | | | 變動日期 2025年11月11日 | | | | | | | | 於下列日期結束時的結存 (註5及6) 2025年11月11日 | 869,831,722 | | 23,637,000 | | 893,468,722 | | | B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) | | | | | | ...

Core Points - The company, Heptagon Pharmaceuticals-B, repurchased 400,000 shares on November 7 at a price range of HKD 11.980 to HKD 12.700, totaling HKD 4.9715 million [2] - The stock closed at HKD 12.570 on the same day, reflecting a decline of 3.16%, with a total trading volume of HKD 130 million [2] - Since November 6, the company has conducted share buybacks for two consecutive days, totaling 500,000 shares and an aggregate amount of HKD 6.2497 million, with a cumulative decline of 0.87% in stock price during this period [2] Buyback Summary - The company has executed a total of 59 buybacks this year, amounting to 23.893 million shares and a total expenditure of HKD 170 million [3] - Detailed buyback transactions include: - November 7: 40,000 shares at a maximum price of HKD 12.700 and a minimum of HKD 11.980, totaling HKD 497.15 thousand [3] - November 6: 10,000 shares at a maximum price of HKD 12.990 and a minimum of HKD 12.610, totaling HKD 127.82 thousand [3] - November 4: 20,000 shares at a maximum price of HKD 13.220 and a minimum of HKD 12.770, totaling HKD 258.49 thousand [3]